Arrowhead Pharmaceuticals (ARWR) is back in focus after new clinical and regulatory updates around its siRNA platform, including fresh data for plozasiran and ARO-INHBE that were shared at recent European medical meetings.

Despite the clinical momentum around plozasiran and ARO-INHBE, short term trading has cooled, with the 7 day share price return down 6.2% and the 30 day share price return down 7.6%, even as the 1 year total shareholder return is very large. Overall, recent weakness follows a sharp upswing, with a 90 day share price return of 22.2% and a 3 year total shareholder return of 106.9%, so momentum looks more like a pause after a big rerating rather than a collapse in confidence.

If Arrowhead's siRNA progress has caught your eye, it could be a good moment to widen the lens and see how other healthcare AI opportunities stack up using the 39 healthcare AI stocks

With Arrowhead now valued at around US$10.6b and the stock sitting roughly 20% below the average analyst price target, investors face a key question: is the siRNA pipeline underappreciated, or is the market already accounting for future growth in the valuation?

Most Popular Narrative: 14.1% Overvalued

Arrowhead's most followed valuation narrative places fair value at about $64.08 per share, which sits below the latest close at $73.09 and frames the stock as priced ahead of that model.

Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, positions the company to potentially capitalize on rising demand for treatments driven by an aging population and increasing prevalence of chronic and genetic diseases, which could significantly accelerate revenue growth as approvals and launches materialize.

Curious what justifies paying above this fair value line. The narrative leans heavily on rapid revenue expansion, stronger margins, and a rich future earnings multiple that assumes those goals land.

Result: Fair Value of $64.08 (OVERVALUED)

However, this hinges on clinical and commercial execution, so any setback in late stage trials or weaker than expected uptake for plozasiran could quickly challenge that optimism.

Another Angle On Valuation

The community narrative sees Arrowhead as about 14.1% overvalued based on future earnings assumptions, but the SWS DCF model points the other way, with a fair value estimate of $181.11 per share versus the current $73.09. This suggests the stock trades at a steep discount if those cash flow forecasts hold up. That kind of gap raises a simple question: which story do you trust more, the earnings multiple or the cash flow math?

Next Steps

With both bullish and cautious voices in play, this is a moment to review the numbers yourself and decide which story feels more convincing. To see the full balance of risks and potential upside in one place, check out the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

Do not stop at one stock story. Use focused screens to surface fresh opportunities that fit your style before the market pays closer attention.

• Target overlooked growth by scanning a screener containing 22 high quality undiscovered gems that filters for strong fundamentals hiding outside the usual watchlists.
• Build resilience into your portfolio by checking a 64 resilient stocks with low risk scores that highlights companies with steadier risk profiles.
• Strengthen your income stream by reviewing a 9 dividend fortresses that focuses on higher yielding companies with robust payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.